Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Webcasts|November 15, 2023

Achieve Higher mAb Titers with BalanCD CHO Perfusion and BalanCD CHO DG44

Author(s)Fujifilm

Webinar Date/Time: Wed, Dec 6, 2023 11:00 AM EST

Discover the latest in cell culture media solutions.

Register Free: https://www.biopharminternational.com/bp_w/mAb-titers

Event Overview:

Efficient production of monoclonal antibodies (mAbs) in CHO cells requires optimized cell culture solutions upstream. Whether it is fed-batch or perfusion processes for the commercial manufacture of biomolecule therapeutics, identifying an appropriate medium for a cell culture process is key for successful scale-up and manufacture.


Introducing chemically defined (CD) media that deliver increased cell productivities in perfusion and fed-batch modes for bioprocessing applications: BalanCD CHO Perfusion and BalanCD CHO DG44 from FUJIFILM Irvine Scientific. Designed to support high cell density and high steady-state cultures for improved cell-specific productivities, these high-performing media provide cost-effective solutions for mAb production.


Key Learning Objectives:

  • Optimize CHO fed-batch and perfusion cultures for high cell density with CD media.
  • Maximize cell growth, titer, and cell-specific productivity for fed-batch and perfusion processes.
  • Achieve cost-effective production of biotherapeutics.

Improve perfusion productivities at higher steady-states by optimizing perfusion culture parameters in a push-to-low strategy.

Speaker:

Dr. Luis Rodriguez
R&D Manager, Bioproduction
FUJIFILM Irvine Scientific

Dr Luis Rodriguez heads the life science bioprocessing team to lead the development of new media, advance process improvements, and provide technical support for the production of biotherapeutics. Dr Rodriguez received his B.S. in Cell and Molecular Biology from California State University, Northridge and his PhD in Biochemistry, Molecular, and Cellular Biology from Cornell University.

Register Free: https://www.biopharminternational.com/bp_w/mAb-titers


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.